On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans

被引：76

作者：

Sasisekharan R. ^{[1
,4
]}

Ernst S. ^{[2
]}

Venkataraman G. ^{[3
]}

机构：

[1] Division of Toxicology, Center for Biomedical Engineering, Whitaker Coll. Hlth. Sci. Technol., Cambridge

[2] Department of Chemical Engineering, Massachusetts Inst. of Technology, Cambridge

[3] Harvard-MIT Div. Hlth. Sci. Technol., Massachusetts Inst. of Technology, Cambridge

[4] MIT, Building E18-568, Cambridge, MA 02139

来源：

Angiogenesis | 1997年 / 1卷 / 1期

关键词：

Angiogenesis; Dimerization; Extracellular matrix; Fibroblast growth factor; Heparan sulfate; Heparin; Receptor; Signal transduction;

D O I：

10.1023/A:1018318914258

中图分类号：

学科分类号：

摘要：

The activity of several angiogenic factors, like fibroblast growth factors (FGF), is modulated by heparin-like glycosaminoglycans (HLGAGs), which are acidic polysaccharides present in the extracellular matrix and at the cell surface. FGF binds to HLGAG in the matrix, where it is sequestered in a protected and inactive form, and at the cell surface, where it activates its cognate signaling receptor. Here we review recent progress in elucidating how HLGAG regulates FGF-induced signal transduction. Data from crystal structures of FGF complexed to active and inactive oligosaccharides is analyzed in the context of current models for HLGAG modulation of FGF activity. We propose that FGF can dimerize in several different modes, stabilized by HLGAGs. Individual dimer modes may represent active or inactive FGF and it is possible that different HLGAGs preferentially stabilize different FGF dimer modes. Understanding HLGAG-FGF interactions can provide leverage for new approaches to therapeutic control of angiogenesis.

引用

页码：45 / 54

页数：9

共 66 条

[1] Lin C.Q., Bissell M., Multi-faceted regulation of cell differentiation by extracellular matrix, FASEB J., 7, pp. 737-743, (1993)
[2] Folkman J., Clinical applications of research on angiogenesis, N Engl J Med, 333, pp. 1757-1763, (1995)
[3] Hanahan D., Folkman J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, pp. 353-364, (1996)
[4] O'Reilly M.S., Boehm T., Shing Y., Et al., Endostatin: An endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, pp. 277-285, (1997)
[5] Hahnenberger R., Jakobson A.M., Ansari A., Et al., Low-sulphated oligosaccharides derived from heparan sulphate inhibit normal angiogenesis, Glycobiology, 3, pp. 567-573, (1993)
[6] Lepri A., Benelli U., Bernardini N., Et al., Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization, J Ocul Pharmacol, 10, pp. 273-280, (1994)
[7] Norrby K., Sorbo J., Heparain enhance angiogenesis by a systemic mode of action, Int J Exp Pathol, 73, pp. 147-155, (1992)
[8] Sasisekharan R., Moses M.A., Nugent M.A., Et al., Heparinase inhibits neovascularization, Proc Natl Acad Sci USA, 91, pp. 1524-1528, (1994)
[9] Baird A., Bohlen P., Fibroblast growth factors, Peptide Growth Factors and Their Receptors I, pp. 369-418, (1990)
[10] Basilico C., Moscatelli D., The FGF family of growth factors and oncogenes, Adv Cancer Res, 59, pp. 115-165, (1992)

← 1 2 3 4 5 6 7 →